A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples